BANBZ Stock Overview
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for BANBZ from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Bachem Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 61.25 |
| 52 Week High | CHF 91.60 |
| 52 Week Low | CHF 53.95 |
| Beta | 0.72 |
| 1 Month Change | -9.33% |
| 3 Month Change | -14.22% |
| 1 Year Change | -4.60% |
| 3 Year Change | -54.43% |
| 5 Year Change | n/a |
| Change since IPO | 673.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| BANBZ | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -7.1% | -8.8% | -2.6% |
| 1Y | -4.6% | -29.8% | 2.7% |
Return vs Industry: BANBZ exceeded the UK Life Sciences industry which returned -27% over the past year.
Return vs Market: BANBZ underperformed the UK Market which returned 3.5% over the past year.
Price Volatility
| BANBZ volatility | |
|---|---|
| BANBZ Average Weekly Movement | 4.3% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BANBZ has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: BANBZ's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 2,009 | Thomas Meier | www.bachem.com |
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding AG Fundamentals Summary
| BANBZ fundamental statistics | |
|---|---|
| Market cap | CHF 4.58b |
| Earnings (TTM) | CHF 113.57m |
| Revenue (TTM) | CHF 577.77m |
40.4x
P/E Ratio7.9x
P/S RatioIs BANBZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BANBZ income statement (TTM) | |
|---|---|
| Revenue | CHF 577.77m |
| Cost of Revenue | CHF 398.41m |
| Gross Profit | CHF 179.36m |
| Other Expenses | CHF 65.79m |
| Earnings | CHF 113.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | 1.51 |
| Gross Margin | 31.04% |
| Net Profit Margin | 19.66% |
| Debt/Equity Ratio | 0% |
How did BANBZ perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield53%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 15:09 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bachem Holding AG is covered by 23 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantin Wiechert | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Markus Mayer | Baader Helvea Equity Research |